FDA Approves VYVGART for All Adult gMG Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ARGX?
Source: Newsfilter
- Indication Expansion: VYVGART and VYVGART Hytrulo received FDA approval for all adult generalized myasthenia gravis (gMG) patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients, marking a significant advancement in addressing the needs of gMG patients.
- Clinical Study Results: In the ADAPT SERON study, patients treated with VYVGART achieved a significant 3.35-point improvement in MG-ADL total score at week 4 (p=0.0068), demonstrating the drug's effectiveness in improving daily living activities and further solidifying its market position.
- Good Safety Profile: VYVGART exhibited good tolerability across all patient types, with safety consistent with the established profile in anti-AChR-Ab positive gMG patients, enhancing physician confidence and simplifying treatment decisions.
- Patient Support Program: argenx launched the My VYVGART Path patient support program to assist patients and healthcare providers in accessing the medication, offering disease education, access support, and financial assistance, reflecting the company's commitment to patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARGX
Wall Street analysts forecast ARGX stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 782.170
Low
858.00
Averages
1048
High
1317
Current: 782.170
Low
858.00
Averages
1048
High
1317
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
argenx SE Receives FDA Approval for VYVGART Label Expansion
- FDA Label Expansion: The U.S. FDA has approved VYVGART and VYVGART Hytrulo for all adult generalized myasthenia gravis (gMG) patients, covering all antibody subtypes, marking a significant advancement in treatment options.
- Clinical Trial Results: In the ADAPT SERON study, patients treated with VYVGART showed statistically significant improvements, with a 3.35-point enhancement in MG-ADL total score at week 4, demonstrating the treatment's effectiveness and sustainability.
- Significant Sales Growth: Argenx reported $1.3 billion in global net sales for the VYVGART franchise in Q1 2026, reflecting a 63% year-over-year increase, indicating strong market demand and product acceptance.
- Broad Market Potential: This approval positions VYVGART as the first treatment available for all gMG patients, expected to further drive sales growth and solidify the company's market position in the rare disease sector.
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
FDA Approves VYVGART for All Adult gMG Patients
- Indication Expansion: VYVGART and VYVGART Hytrulo received FDA approval for all adult generalized myasthenia gravis (gMG) patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients, marking a significant advancement in addressing the needs of gMG patients.
- Clinical Study Results: In the ADAPT SERON study, patients treated with VYVGART achieved a significant 3.35-point improvement in MG-ADL total score at week 4 (p=0.0068), demonstrating the drug's effectiveness in improving daily living activities and further solidifying its market position.
- Good Safety Profile: VYVGART exhibited good tolerability across all patient types, with safety consistent with the established profile in anti-AChR-Ab positive gMG patients, enhancing physician confidence and simplifying treatment decisions.
- Patient Support Program: argenx launched the My VYVGART Path patient support program to assist patients and healthcare providers in accessing the medication, offering disease education, access support, and financial assistance, reflecting the company's commitment to patient care.
See More
argenx SE Q1 Earnings Beat Expectations
- Earnings Beat: argenx SE reported a Q1 GAAP EPS of $5.52, exceeding expectations by $0.31, indicating strong profitability that boosts investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved $1.3 billion in revenue for Q1, a 64.6% year-over-year increase, although it fell short of expectations by $10 million, suggesting increased market competition may impact future revenue forecasts.
- Strong Cash Position: As of March 31, 2026, argenx held $4.9 billion in cash, cash equivalents, and current financial assets, up from $4.4 billion at the end of 2025, reflecting robust cash management practices that support operational stability.
- Financial Health Indicators: The increase in cash and equivalents is primarily driven by ongoing profitability, enhancing the company's capacity for investment in R&D and market expansion, thereby laying a solid foundation for future growth.
See More
argenx CEO to Present at BofA Healthcare Conference
- Presentation Schedule: argenx CEO Karen Massey will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026, at 10:40 a.m. PT, showcasing the company's latest advancements in severe autoimmune diseases, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be accessible via a live webcast on the investors section of the argenx website, and a replay will be available for approximately 30 days post-event, allowing investors who miss the live session to access key information and enhancing the company's transparency.
- Company Mission and Vision: argenx is committed to improving the lives of people suffering from severe autoimmune diseases, partnering with leading academic researchers to translate immunology breakthroughs into a portfolio of novel antibody-based medicines, demonstrating its innovative capabilities in the biopharmaceutical sector.
- Product Development Progress: As the developer of the first approved neonatal Fc receptor (FcRn) blocker, argenx is evaluating its broad potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines, showcasing the company's strategic positioning in the therapeutic landscape.
See More
argenx SE to Announce Q1 Earnings on May 7
- Earnings Announcement Date: argenx SE is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at $4.92, reflecting a substantial year-over-year growth of 90.7%, indicating strong profitability potential.
- Revenue Expectations: The anticipated revenue for Q1 is $1.31 billion, representing a 60.8% year-over-year increase; however, the revenue estimates have faced 10 downward revisions in the last three months, suggesting cautious market sentiment regarding future growth.
- EPS Revision Dynamics: Over the past three months, EPS estimates have seen one upward revision and eight downward adjustments, highlighting analyst discrepancies regarding the company's profitability outlook, which could impact investor confidence.
- GAAP Financial Performance: In Q4 2025, argenx SE reported a GAAP EPS of $8.02, beating estimates by $1.70, although revenue of $1.29 billion fell short by $10 million, showcasing strong earnings performance but challenges in revenue growth.
See More
argenx SE Receives FDA Approval for VYVGART Label Expansion
- FDA Label Expansion: The U.S. FDA has approved VYVGART and VYVGART Hytrulo for all adult generalized myasthenia gravis (gMG) patients, covering all antibody subtypes, marking a significant advancement in treatment options.
- Clinical Trial Results: In the ADAPT SERON study, patients treated with VYVGART showed statistically significant improvements, with a 3.35-point enhancement in MG-ADL total score at week 4, demonstrating the treatment's effectiveness and sustainability.
- Significant Sales Growth: Argenx reported $1.3 billion in global net sales for the VYVGART franchise in Q1 2026, reflecting a 63% year-over-year increase, indicating strong market demand and product acceptance.
- Broad Market Potential: This approval positions VYVGART as the first treatment available for all gMG patients, expected to further drive sales growth and solidify the company's market position in the rare disease sector.
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
FDA Approves VYVGART for All Adult gMG Patients
- Indication Expansion: VYVGART and VYVGART Hytrulo received FDA approval for all adult generalized myasthenia gravis (gMG) patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients, marking a significant advancement in addressing the needs of gMG patients.
- Clinical Study Results: In the ADAPT SERON study, patients treated with VYVGART achieved a significant 3.35-point improvement in MG-ADL total score at week 4 (p=0.0068), demonstrating the drug's effectiveness in improving daily living activities and further solidifying its market position.
- Good Safety Profile: VYVGART exhibited good tolerability across all patient types, with safety consistent with the established profile in anti-AChR-Ab positive gMG patients, enhancing physician confidence and simplifying treatment decisions.
- Patient Support Program: argenx launched the My VYVGART Path patient support program to assist patients and healthcare providers in accessing the medication, offering disease education, access support, and financial assistance, reflecting the company's commitment to patient care.
See More
argenx SE Q1 Earnings Beat Expectations
- Earnings Beat: argenx SE reported a Q1 GAAP EPS of $5.52, exceeding expectations by $0.31, indicating strong profitability that boosts investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved $1.3 billion in revenue for Q1, a 64.6% year-over-year increase, although it fell short of expectations by $10 million, suggesting increased market competition may impact future revenue forecasts.
- Strong Cash Position: As of March 31, 2026, argenx held $4.9 billion in cash, cash equivalents, and current financial assets, up from $4.4 billion at the end of 2025, reflecting robust cash management practices that support operational stability.
- Financial Health Indicators: The increase in cash and equivalents is primarily driven by ongoing profitability, enhancing the company's capacity for investment in R&D and market expansion, thereby laying a solid foundation for future growth.
See More
argenx CEO to Present at BofA Healthcare Conference
- Presentation Schedule: argenx CEO Karen Massey will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026, at 10:40 a.m. PT, showcasing the company's latest advancements in severe autoimmune diseases, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be accessible via a live webcast on the investors section of the argenx website, and a replay will be available for approximately 30 days post-event, allowing investors who miss the live session to access key information and enhancing the company's transparency.
- Company Mission and Vision: argenx is committed to improving the lives of people suffering from severe autoimmune diseases, partnering with leading academic researchers to translate immunology breakthroughs into a portfolio of novel antibody-based medicines, demonstrating its innovative capabilities in the biopharmaceutical sector.
- Product Development Progress: As the developer of the first approved neonatal Fc receptor (FcRn) blocker, argenx is evaluating its broad potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines, showcasing the company's strategic positioning in the therapeutic landscape.
See More
argenx SE to Announce Q1 Earnings on May 7
- Earnings Announcement Date: argenx SE is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at $4.92, reflecting a substantial year-over-year growth of 90.7%, indicating strong profitability potential.
- Revenue Expectations: The anticipated revenue for Q1 is $1.31 billion, representing a 60.8% year-over-year increase; however, the revenue estimates have faced 10 downward revisions in the last three months, suggesting cautious market sentiment regarding future growth.
- EPS Revision Dynamics: Over the past three months, EPS estimates have seen one upward revision and eight downward adjustments, highlighting analyst discrepancies regarding the company's profitability outlook, which could impact investor confidence.
- GAAP Financial Performance: In Q4 2025, argenx SE reported a GAAP EPS of $8.02, beating estimates by $1.70, although revenue of $1.29 billion fell short by $10 million, showcasing strong earnings performance but challenges in revenue growth.
See More
